Filing Details
- Accession Number:
- 0001209191-20-028268
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-05-11 16:25:07
- Reporting Period:
- 2020-05-07
- Accepted Time:
- 2020-05-11 16:25:07
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1503802 | Karyopharm Therapeutics Inc. | KPTI | Pharmaceutical Preparations (2834) | 263931704 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1603510 | Brett Christopher Primiano | C/O Karyopharm Therapeutics Inc. 85 Wells Avenue Newton MA 02459 | Evp, Cbo, Gc & Secretary | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2020-05-07 | 6,714 | $19.62 | 4,649 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2020-05-07 | 2,946 | $6.54 | 7,595 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-05-07 | 2,946 | $20.00 | 4,649 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2020-05-07 | 2,946 | $0.00 | 2,946 | $6.54 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 10,054 | 2026-01-14 | No | 4 | M | Direct |
Footnotes
- These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $19.37 to $20.00, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- Includes 996 shares acquired under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan.
- This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on January 15, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter.
Billionaire Hedge Funds
